Nurse Practitioner Program year 2025 Reported 2023–2025 Source: CMS Open Payments, 2026 publication

Isaura Cabrera

Nurse Practitioner McDonough, GA Nurse Practitioner

NPI 1649054008 CMS profile 11516865

3333 Jodeco Rd Ste A, McDonough, GA 30253

Open in the dashboard

General payments

$1,192

64 records reported · program years 2023–2025

Research payments

$0

Paid to them · None reported · program years 2023–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Isaura Cabrera of McDonough, GA is reported in the CMS Open Payments database as having received $1,192 across 64 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 72nd percentile of Nurse Practitioner profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

3 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $717 38
2024 General $366 20
2023 General $109 6

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Isaura Cabrera
  • Nurse Practitioner median
  • Middle half of Nurse Practitioner
  • National median

In program year 2025, general payments to Isaura Cabrera were reported at $717. Among 41,044 Nurse Practitioner profiles paid that year, the median was $174 and the middle half received between $55 and $557.

Show as a table
Year Isaura Cabrera Nurse Practitioner median Middle half National median
2019 $0 $50 $22–$97 $163
2020 $0 $40 $16–$108 $114
2021 $0 $135 $40–$426 $132
2022 $0 $152 $48–$470 $149
2023 $109 $166 $54–$529 $160
2024 $366 $173 $55–$556 $164
2025 $717 $174 $55–$557 $169

Breakdown

Who paid General payments · program years 2023–2025
  1. Pfizer Inc. $315 20 payments
  2. Merck Sharp & Dohme Corporation $172 9 payments
  3. ZOLL Services LLC (A/K/A ZOLL LifeCor Corp) $158 7 payments
  4. Novartis Pharmaceuticals Corporation $130 8 payments
  5. Boehringer Ingelheim Pharmaceuticals, Inc. $123 6 payments
  6. Actelion Pharmaceuticals US, Inc. $96 5 payments
  7. AstraZeneca Pharmaceuticals LP $36 1 payment
  8. Boston Scientific Corporation $31 2 payments
  9. Vital Connect, Inc $29 1 payment
  10. Abiomed $29 1 payment
  11. Other $73 4 payments

Every payment, record by record

What the payments were for General payments · program years 2023–2025
  1. Food and Beverage $1,192 64 payments
Products named General payments · program years 2023–2025
  1. VYNDAQEL $160 9 payments
  2. LifeVest $158 7 payments
  3. ELIQUIS $155 11 payments
  4. LEQVIO $130 8 payments
  5. JARDIANCE $123 6 payments
  6. VERQUVO $96 5 payments
  7. UPTRAVI $78 4 payments
  8. OPSUMIT $76 4 payments
  9. WINREVAIR $51 3 payments
  10. PAXLOVID $45 3 payments
  11. Other $248 12 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 26 drugs

Part D claims

1,051

Median for Nurse Practitioner: 389

Drug cost

$97,011

Median for Nurse Practitioner: $21,885

Branded share of claims

16.4%

Median for Nurse Practitioner: 19.6%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Eliquis Apixaban Brand 51 $46,809
Entresto Sacubitril/Valsartan Brand 21 $20,006
Jardiance Empagliflozin Brand 12 $9,025
Farxiga Dapagliflozin Propanediol Brand 14 $8,653
Repatha Sureclick Evolocumab Brand 11 $6,055
Valsartan Generic 40 $878
Metoprolol Succinate Generic 115 $788
Amlodipine Besylate Generic 139 $583
Atorvastatin Calcium Generic 82 $503
Hydralazine Hcl Generic 45 $405

The 10 drugs with the highest cost, of 26 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 229,976 Part D prescribers listed as Nurse Practitioner; they describe a distribution and say nothing about conduct.

Payments and prescribing

First 5 of 10 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
LEQVIO
  • Novartis Pharmaceuticals Corporation $70
$70 — —
ELIQUIS
  • PFIZER INC. $41
$41 51 —
FARXIGA
  • AstraZeneca Pharmaceuticals LP $36
$36 14 —
JARDIANCE
  • Boehringer Ingelheim Pharmaceuticals, Inc. $32
$32 12 —
WINREVAIR
  • Merck Sharp & Dohme Corporation $18
$18 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See all 10 in the dashboard with a free account

Records

64 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Nurse Practitioner in Georgia

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record